ATE523199T1 - Pyridazinverbindungen und verfahren - Google Patents

Pyridazinverbindungen und verfahren

Info

Publication number
ATE523199T1
ATE523199T1 AT05823123T AT05823123T ATE523199T1 AT E523199 T1 ATE523199 T1 AT E523199T1 AT 05823123 T AT05823123 T AT 05823123T AT 05823123 T AT05823123 T AT 05823123T AT E523199 T1 ATE523199 T1 AT E523199T1
Authority
AT
Austria
Prior art keywords
methods
compositions
same
pyridazine compounds
compounds
Prior art date
Application number
AT05823123T
Other languages
English (en)
Inventor
D Martin Watterson
Eldik Linda Van
Jacques Haiech
Marcel Hibert
Jean-Jacques Bourguignon
Anastasia Velentza
Wenhui Hu
Magdelena Zasadzki
Original Assignee
Univ Northwestern
Univ Strasbourg
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northwestern, Univ Strasbourg, Centre Nat Rech Scient filed Critical Univ Northwestern
Application granted granted Critical
Publication of ATE523199T1 publication Critical patent/ATE523199T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/36—Benzo-cinnolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT05823123T 2004-11-02 2005-11-02 Pyridazinverbindungen und verfahren ATE523199T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62434604P 2004-11-02 2004-11-02
US72337605P 2005-10-04 2005-10-04
PCT/US2005/039476 WO2006050359A2 (en) 2004-11-02 2005-11-02 Pyridazine compounds and methods

Publications (1)

Publication Number Publication Date
ATE523199T1 true ATE523199T1 (de) 2011-09-15

Family

ID=36319764

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05823123T ATE523199T1 (de) 2004-11-02 2005-11-02 Pyridazinverbindungen und verfahren

Country Status (6)

Country Link
US (1) US8063047B2 (de)
EP (1) EP1812007B1 (de)
JP (1) JP2008518955A (de)
AT (1) ATE523199T1 (de)
CA (1) CA2589102C (de)
WO (1) WO2006050359A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100210590A1 (en) * 1995-09-27 2010-08-19 Northwestern University Compositions and treatments for seizure-related disorders
EP1430033A4 (de) 2001-08-31 2004-12-15 Univ Northwestern Entzündunshemmende und proteinkinaseinhibierende zusammensetzung und deren verwendung
ATE523199T1 (de) 2004-11-02 2011-09-15 Univ Northwestern Pyridazinverbindungen und verfahren
EP1812408B1 (de) 2004-11-02 2013-10-09 Northwestern University Pyridazinverbindungen, zusammensetzungen und verfahren
CA2650711A1 (en) 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
CA2650704A1 (en) * 2006-04-28 2007-11-08 Northwestern University Salts of pyridazine compounds
CA2650625A1 (en) 2006-04-28 2007-11-08 Northwestern University Formulations containing pyridazine compounds for treating neuroinflammatory diseases
EP3521284B1 (de) 2013-03-15 2020-12-02 The Trustees of Columbia University in the City of New York Pyrazin-verbindungen als map-kinasemodulatoren und verwendungen davon

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US39000A (en) * 1863-06-23 Improved paint composition
NL92451C (de) * 1955-08-19
US3464988A (en) * 1968-01-11 1969-09-02 Bristol Myers Co 3-hydrazinobenzo(h)cinnolines and 3 - hydrazinobenzocyclohepta-(5,6-c)pyridazines
GB1345880A (en) * 1971-06-18 1974-02-06 Cepbepe Pyridazine derivatives
FR2510998B1 (fr) * 1981-08-07 1986-01-10 Sanofi Sa Nouveaux derives amines de la pyridazine, leur procede de preparation et les medicaments, a action desinhibitrice, qui en comportent
FR2511366A1 (fr) * 1981-08-11 1983-02-18 Sanofi Sa Nouveaux derives de la pyridazine, leur procede de preparation et les medicaments, actifs sur le systeme nerveux central, qui en contiennent
DE3217325A1 (de) 1982-05-08 1983-11-10 Hoechst Ag, 6230 Frankfurt 3-amino-6-aryl-1,2,4-triazolo(4,3-b)-pyridazine, ihre herstellung und ihre verwendung
FR2540113A1 (fr) * 1983-01-27 1984-08-03 Sanofi Sa Acides derives de la pyridazine actifs sur le systeme nerveux central
US4562196A (en) * 1984-04-06 1985-12-31 Nelson Research & Development 2,4-Diaminopyridine as a pharmacologic agent
US4631286A (en) * 1984-10-25 1986-12-23 Hoechst-Roussel Pharmaceuticals Inc. 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds
EP0179383B1 (de) * 1984-10-25 1991-05-29 Hoechst-Roussel Pharmaceuticals Incorporated 9-Amino-1,2,3,4-tetrahydroacridin-1-ol und verwandte Verbindungen, Verfahren zu ihrer Herstellung und Verwendung als Arzneimittel
US4835275A (en) * 1984-10-25 1989-05-30 Hoechst-Roussel Pharmaceuticals, Inc. Method of preparing 9-amino-1,2,3,4,-tetrahydroacridin-1-ones and related compounds
US4754050A (en) * 1984-10-25 1988-06-28 Hoechst-Roussel Pharmaceuticals, Inc. 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds
AU578496B2 (en) * 1984-11-01 1988-10-27 Smith Kline & French Laboratories Limited Tricyclic heterocyclic compounds
IL74497A (en) * 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
ES8802151A1 (es) 1985-07-31 1988-04-01 Janssen Pharmaceutica Nv Un procedimiento para la preparacion de nuevos piridazinaminas.
JPH0650381B2 (ja) 1985-08-05 1994-06-29 富士写真フイルム株式会社 ハロゲン化銀カラ−感光材料の処理方法
US4654343A (en) * 1985-10-31 1987-03-31 American Cyanamid Company N-substituted-N[3-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)phenyl]alkanamides, carbamates and ureas
FR2601011B1 (fr) * 1986-07-03 1988-10-28 Sanofi Sa Nouveaux derives tricycliques agonistes des recepteurs cholinergiques et medicaments en contenant
US4816456A (en) * 1986-10-01 1989-03-28 Summers William K Administration of monoamine acridines in cholinergic neuronal deficit states
JP2531678B2 (ja) * 1987-05-27 1996-09-04 吉富製薬株式会社 トリアゾロピリダジン誘導体
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
DE3882982T2 (de) * 1987-11-02 1993-11-25 Yoshitomi Pharmaceutical Kondensierte pyridazin-verbindungen und deren verwendung als arzneimittel.
PT93060B (pt) 1989-02-07 1995-12-29 Sanofi Sa Processo para a obtencao de derivados de piridazina e de composicoes farmaceuticas que os contem
US5693668A (en) * 1989-06-22 1997-12-02 Merrell Pharmaceuticals Inc. Acetylcholinesterase inhibitors
JP3075566B2 (ja) 1990-05-15 2000-08-14 エーザイ株式会社 光学活性インダノン誘導体
JP2965675B2 (ja) 1990-11-21 1999-10-18 エーザイ株式会社 （―）―１―ベンジル―４―〔（５，６―ジメトキシ―１―インダノン）―２―イル〕メチルピペリジンの製造方法
US5104880A (en) * 1991-05-01 1992-04-14 Mayo Foundation For Medical Education And Research Huperzine a analogs as acetylcholinesterase inhibitors
JP3424180B2 (ja) * 1993-02-23 2003-07-07 独立行政法人物質・材料研究機構 Ｐ型熱発電材料
DE69408598T2 (de) 1993-06-08 1998-09-17 Vertex Pharmaceuticals Inc Cam Pyridazine als Interleukin-1-beta Verwandlungsenzym Inhibitoren
US5554780A (en) * 1994-05-05 1996-09-10 Merrell Pharmaceuticals Inc. Process for the preparation of 1-(3-trialkylsilylphenyl)-2,2,2-trifluoromethyl ethanone derivatives
CN1125725A (zh) * 1994-12-28 1996-07-03 中国科学院上海药物研究所 一类海克林碱衍生物及它的用途
EP0749972A1 (de) * 1995-06-21 1996-12-27 Merrell Pharmaceuticals Inc. Verfahren zur Herstellung von 1-(3-trialkylsilylphenyl)-2,2,2-trifluormethylethanonderivaten
CA2282654C (en) 1997-03-03 2009-02-03 Eisai Co., Ltd. Use of cholinesterase inhibitors to treat attention deficit hyperactivity disorder
GB9707693D0 (en) 1997-04-16 1997-06-04 Smithkline Beecham Plc Novel method of treatment
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
US6194403B1 (en) * 1999-09-09 2001-02-27 Unitech Pharmaceuticals, Inc. Tacrine derivatives for treating Alzheimer's disease
US6602872B1 (en) 1999-12-13 2003-08-05 Merck & Co., Inc. Substituted pyridazines having cytokine inhibitory activity
KR100876069B1 (ko) 2000-09-15 2008-12-26 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 약제학적 조성물
EP1430033A4 (de) * 2001-08-31 2004-12-15 Univ Northwestern Entzündunshemmende und proteinkinaseinhibierende zusammensetzung und deren verwendung
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
JP2004096485A (ja) * 2002-08-30 2004-03-25 Sharp Corp 電話制御システム
FR2847253B1 (fr) 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
KR20050085535A (ko) 2002-12-11 2005-08-29 파마시아 앤드 업존 캄파니 엘엘씨 알파 7 니코틴성 아세틸콜린 수용체 아고니스트와 다른화합물의 조합물을 사용한 질환의 치료 방법
FR2848452B1 (fr) 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
DE602004011767T2 (de) 2003-05-16 2009-02-19 Merck Sharp & Dohme Ltd., Hoddesdon Cyclohexylsulfone als gamma-sekretase-inhibitoren
US7060698B2 (en) 2003-05-19 2006-06-13 Hoffmann-La Roche Inc. Benzoxazepinone derivatives
AU2004259263B2 (en) 2003-07-29 2010-12-16 High Point Pharmaceuticals, Llc Pyridazinyl- piperazines and their use as histamine H3 receptor ligands
AU2004276050B2 (en) 2003-09-24 2010-02-25 Merck Sharp & Dohme Limited Gamma-secretase inhibitors
RU2006126122A (ru) 2003-12-19 2008-01-27 Бристол-Маерс Сквибб Компани (Us) Азабициклические гетероциклы как модуляторы каннабиоидного рецептора
TW200528455A (en) 2003-12-19 2005-09-01 Bristol Myers Squibb Co Azabicyclic heterocycles as cannabinoid receptor modulators
US7220858B2 (en) * 2003-12-23 2007-05-22 Barbeau Pharma, Inc. Synthesis of hydrazine and chlorinated derivatives of bicyclic pyridazines
MY145822A (en) 2004-08-13 2012-04-30 Neurogen Corp Substituted biaryl piperazinyl-pyridine analogues
ATE523199T1 (de) 2004-11-02 2011-09-15 Univ Northwestern Pyridazinverbindungen und verfahren
EP1812408B1 (de) * 2004-11-02 2013-10-09 Northwestern University Pyridazinverbindungen, zusammensetzungen und verfahren
EP2019649A4 (de) 2006-04-27 2012-09-19 Narmada R Shenoy Zusammensetzungen und verfahren zur behandlung oder vorbeugung von erkrankungen von körperdurchgangswegen
WO2007130383A2 (en) 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
WO2007127475A2 (en) 2006-04-28 2007-11-08 Northwestern University Pyridazines for demyelinating diseases and neuropathic pain
CA2650625A1 (en) 2006-04-28 2007-11-08 Northwestern University Formulations containing pyridazine compounds for treating neuroinflammatory diseases
CA2650704A1 (en) 2006-04-28 2007-11-08 Northwestern University Salts of pyridazine compounds
CA2650711A1 (en) 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
US7732445B2 (en) * 2006-07-21 2010-06-08 Northwestern University Myosin light chain kinase inhibitor compounds, compostions and related methods of use
AU2008223066A1 (en) 2007-03-02 2008-09-12 Northwestern University Compositions comprising derivatives of 3 -phenylpyridazine for treating seizure-related disorders

Also Published As

Publication number Publication date
EP1812007B1 (de) 2011-09-07
WO2006050359A3 (en) 2006-08-10
EP1812007A4 (de) 2009-04-01
US8063047B2 (en) 2011-11-22
CA2589102A1 (en) 2006-05-11
US20090029985A1 (en) 2009-01-29
EP1812007A2 (de) 2007-08-01
WO2006050359A2 (en) 2006-05-11
CA2589102C (en) 2013-08-13
JP2008518955A (ja) 2008-06-05

Similar Documents

Publication Publication Date Title
WO2006050389A3 (en) Pyridazine compounds, compositions and methods
WO2007127474A3 (en) Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
NO20060230L (no) Nye aminobenzofenonforbindelser
ATE523199T1 (de) Pyridazinverbindungen und verfahren
TW200728305A (en) Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
ATE512147T1 (de) Makrozyklische aminiopyridyl-beta-sekretase- hemmer zur behandlung von morbus alzheimer
WO2007130383A3 (en) Compositions and treatments using pyridazine compounds and secretases
CY1111070T1 (el) Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace)
ATE475650T1 (de) Positive allosterische chinolon-m1- rezeptormodulatoren
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
NO20081434L (no) 5-(fenylisoksazolyletoksy)-triazol-3-yl substituert pyridinsammensetninger for behandling av neurologisk, psykiatrisk eller smerteforstyrrelser
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
EA200601223A1 (ru) Производные сульфонамида для лечения заболеваний
DE60315677D1 (de) Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
TW200724543A (en) Heterocyclic compounds and their uses as therapeutic agents
ATE517861T1 (de) Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
EA200701930A1 (ru) Производные пиримидина для лечения гиперпролиферативных нарушений
WO2005065195A3 (en) Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE504580T1 (de) Malonsäureamidderivate als inhibitoren von g- sekretase zur behandlung von alzheimer-krankheit
NO20054361D0 (no) Benzensylfonamidderivater, fremgangsmate for fremstilling og anvendelse derav for behandlig av smerte
WO2006057945A3 (en) 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties